Content about Autoimmunity

February 4, 2014

The Pharmaceutical Research and Manufacturers of America on Tuesday announced a partnership with the National Institutes of Health that will help spur drug development, the association stated.

WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Tuesday announced a partnership with the National Institutes of Health that will help spur drug development, the association stated. 

The Accelerating Medicines Partnership — an initiative of NIH, several non-profit disease foundations, 10 biopharmaceutical companies and PhRMA — aims to transform the current model for developing new diagnostics and treatments by joining forces to identify and validate promising biological targets of disease. 

January 15, 2014

A new drug for autoimmune diseases from Antares Pharma that the company calls the first of its kind is now available, the drug maker said Wednesday.

EWING, N.J. — A new drug for autoimmune diseases from Antares Pharma that the company calls the first of its kind is now available, the drug maker said Wednesday.

Antares announced the availability of Otrexup for rheumatoid arthritis and psoriasis in adults and polyarticular idiopathic arthritis in children. The company said the drug is the first Food and Drug Administration-approved subcutaneous methotrexate product for once-weekly self-administration. Otrexup, which the FDA approved in October, is available with a single-dose auto injector.

January 14, 2014

An educational program partially conceived by a group focused on lupus research is expected to receive $2 million through a congressional appropriations bill.

NEW YORK — An educational program partially conceived by a group focused on lupus research is expected to receive $2 million through a congressional appropriations bill.

October 7, 2013

The National Psoriasis Foundation and the Arthritis Foundation are presenting the country's first program specifically devoted to psoriatic arthritis this week, the two organizations said Monday.

PORTLAND, Ore. — The National Psoriasis Foundation and the Arthritis Foundation are presenting the country's first program specifically devoted to psoriatic arthritis this week, the two organizations said Monday.

The groups will sponsor the event, Be Joint Smart, at Queens College in New York, on Saturday.

September 24, 2013

Belgian drug maker Ablynx is licensing an experimental treatment for rheumatoid arthritis and lupus to U.S. drug maker AbbVie in a deal worth up to $840 million.

GHENT, Belgium — Belgian drug maker Ablynx is licensing an experimental treatment for rheumatoid arthritis and lupus to U.S. drug maker AbbVie in a deal worth up to $840 million, the companies said.

The two drug makers announced that AbbVie would license the drug ALX-0061 for an upfront payment of $175 million plus milestone payments worth up to $665 million, as well as royalties. The drug belongs to a class known as anti-interleukin-6R nanobodies, which work by targeting an immune-system protein pathway that plays a key role in the inflammation associated with RA.

September 18, 2013

Two organizations are providing an educational program centered on a serious form of arthritis that affects up to 2 million people in the United States.

PORTLAND, Ore. — Two organizations are providing an educational program centered on a serious form of arthritis that affects up to 2 million people in the United States.

The National Psoriasis Foundation and the Arthritis Foundation said they would partner for the second year to educate residents of southern California about psoriatic arthritis, a chronic, inflammatory autoimmune disease that affects about 300,000 people in the state and 98,000 people in the Los Angeles area.

October 17, 2012

Vitamin D supplementation could be considered an immunomodulatory agent for systemic lupus erythematosus, an autoimmune disease characterized not only by skin, joint, neurological and renal symptoms, but also by inflammation of tissue linings in the body, according to a new clinical study published Tuesday in BioMedCentral's open access journal Arthritis Research and Therapy.

LONDON — Vitamin D supplementation could be considered an immunomodulatory agent for systemic lupus erythematosus, an autoimmune disease characterized not only by skin, joint, neurological and renal symptoms, but also by inflammation of tissue linings in the body, according to a new clinical study published Tuesday in BioMedCentral's open access journal Arthritis Research and Therapy

An immunomodulatory agent has an effect on the immune system. 

December 23, 2011

Baxter and Momenta have agreed to partner to develop and market biosimilar drugs to treat cancer, autoimmune disorders and other chronic conditions.

NEW YORK — Baxter and Momenta have agreed to partner to develop and market biosimilar  drugs to treat cancer, autoimmune disorders and other chronic conditions.

December 20, 2011

Israeli drug maker Teva Pharmaceutical Industries is developing a protein that could offer a new way to treat Type 1 diabetes, according to published reports.

NEW YORK — Israeli drug maker Teva Pharmaceutical Industries is developing a protein that could offer a new way to treat Type 1 diabetes, according to published reports.

Type 1 diabetes is an autoimmune disorder in which the immune system attacks the pancreas's beta cells, but the drug, DiaPep277, stops that from happening, according to Bloomberg.

November 7, 2011

The first study to report the effects vitamin D has on the immune system of people with lupus was unveiled Saturday at the American College of Rheumatology Annual Scientific Meeting in Chicago.

CHICAGO — The first study to report the effects vitamin D has on the immune system of people with lupus was unveiled Saturday at the American College of Rheumatology Annual Scientific Meeting here.

The small sample study determined that vitamin D supplementation helped improve cell level counts associated with the disease.

October 11, 2011

Drug makers have 901 biotech drugs under development for more than 100 diseases ranging from cancers and infectious diseases to autoimmune disorders and cardiovascular diseases, the Pharmaceutical Research and Manufacturers of America said.


WASHINGTON — Drug makers have 901 biotech drugs under development for more than 100 diseases ranging from cancers and infectious diseases to autoimmune disorders and cardiovascular diseases, the Pharmaceutical Research and Manufacturers of America said.


April 22, 2011

Many children with Type 1 diabetes have other autoimmune disorders as well, according to published reports.

NEW YORK — Many children with Type 1 diabetes have other autoimmune disorders as well, according to published reports.

Citing findings in a recent study of nearly 500 children published in the journal Diabetes Care, Reuters reported that one-third of children with the disease — an autoimmune disorder in which the immune system attacks the cells of the pancreas — also have such disorders as celiac disease, autoimmune thyroid disease and a disorder of the adrenal glands called Addison’s disease.

February 25, 2011

More than 400 drugs are in late-stage clinical development or awaiting Food and Drug Administration approval as treatments for rare diseases, according to a report by the drug industry lobby.

WASHINGTON — More than 400 drugs are in late-stage clinical development or awaiting Food and Drug Administration approval as treatments for rare diseases, according to a report by the drug industry lobby.

February 3, 2011

Drug maker Eli Lilly and the Juvenile Diabetes Research Foundation will fund research to find ways to regenerate insulin-producing cells in patients with Type 1 diabetes.

INDIANAPOLIS — Drug maker Eli Lilly and the Juvenile Diabetes Research Foundation will fund research to find ways to regenerate insulin-producing cells in patients with Type 1 diabetes.

The two announced Thursday that ideas included finding ways to grow new insulin-producing cells within a person’s body. Type 1 diabetes, also known as juvenile diabetes, is an autoimmune disease in which the immune system attacks beta cells, the cells that allow the body to produce insulin. As many as 3 million people in the United States have Type 1 diabetes.

November 2, 2010

A company that develops drugs for treating autoimmune diseases and cancer has created a scientific...

CAMBRIDGE, Mass. A company that develops drugs for treating autoimmune diseases and cancer has created a scientific advisory board as part of its efforts to create treatments for Type 1 diabetes.

 

Tolerx said the four-member board would support the development of its lead drug candidate, otelixizumab, and guide future research and development in the Type 1 diabetes area.

 

 

August 23, 2010

Swiss drug maker Roche will acquire a U.S. diagnostics company that develops technology used to...

BASEL, Switzerland Swiss drug maker Roche will acquire a U.S. diagnostics company that develops technology used to create images of patients’ tissue samples.

Roche announced that it would acquire all of Sunnyvale, Calif.-based BioImagene for $100 million. BioImagene works in the field of digital pathology, a technology that allows the capturing, management and analysis of images of patients’ tissue samples, creating high-resolution images from glass microscope slides.

January 19, 2010

A group of companies and organizations plan to collaborate to develop new treatments for multiple...